Quanterix Broadens Access to Blood-Based Alzheimer’s Testing Through Exclusive Partnership with Sherman Abrams Laboratory in New Jersey and Surrounding Areas

Quanterix Partners with Sherman Abrams Laboratory to Expand Access to LucentAD Complete Alzheimer’s Blood Testing Across New Jersey and Metro New York

Quanterix Corporation, a company developing advanced ultrasensitive biomarker detection technologies, has announced an exclusive distribution agreement with Sherman Abrams Laboratory, a Brooklyn-based clinical and anatomic pathology laboratory. The collaboration will expand access to Quanterix’s LucentAD® Complete blood tests for patients across New Jersey and surrounding areas, including the broader Metro New York and New Jersey region.

Through the agreement, Sherman Abrams Laboratory will make LucentAD Complete available to its extensive network of referring physicians. The partnership is designed to increase the availability of blood-based testing for Alzheimer’s disease, particularly for individuals who are experiencing signs of cognitive decline or may be at risk of developing the condition but have not yet received a formal diagnosis.

The agreement represents an important step toward improving access to advanced diagnostic testing in a region with a substantial population affected by Alzheimer’s disease. By combining Quanterix’s biomarker testing technology with Sherman Abrams Laboratory’s established clinical laboratory network, the companies aim to help physicians obtain additional information when evaluating patients with potential signs of the disease.

Expanding Access to Blood-Based Alzheimer’s Diagnostics

LucentAD Complete is powered by Quanterix’s proprietary SIMOA® platform, which is designed to measure biomarkers at very low concentrations. The blood-based test is among the early diagnostic offerings developed to evaluate multiple biomarkers associated with Alzheimer’s disease, potentially providing physicians with a more comprehensive picture of a patient’s disease-related risk.

Alzheimer’s disease is a progressive neurological condition that affects memory, thinking, and other cognitive abilities. As the disease advances, individuals may experience increasing difficulties with everyday activities and eventually require substantial support from caregivers and healthcare professionals.

Early identification of Alzheimer’s-related changes can be important for patients, families, and healthcare providers. A timely evaluation may help physicians better understand a patient’s symptoms, determine whether additional diagnostic assessments are appropriate, and consider suitable care and management strategies.

Historically, the evaluation of Alzheimer’s disease has involved a combination of clinical assessments, cognitive testing, medical history reviews, and specialized diagnostic procedures. Access to certain advanced diagnostic methods can be limited by availability, cost, and the need for specialized facilities. Blood-based biomarker tests are emerging as another option that may help simplify aspects of the diagnostic process and expand access to disease-related information.

LucentAD Complete is intended to support this evolving diagnostic landscape by measuring multiple biomarkers associated with Alzheimer’s disease through a blood sample. The use of the SIMOA platform enables sensitive biomarker detection, supporting the assessment of biological signals relevant to the condition.

The test is intended to provide additional information for physicians evaluating patients and should be considered within the broader clinical context. Its availability through Sherman Abrams Laboratory is expected to make this type of testing more accessible to healthcare professionals across the region.

Quanterix Highlights the Importance of Diagnostic Accessibility

Everett Cunningham, Chief Executive Officer of Quanterix, emphasized that improving access to advanced diagnostics is essential to ensuring that blood-based testing can reach the patients who may benefit from it.

“Sherman Abrams Lab understands the patient’s needs and shares our commitment to expanding access to advanced diagnostics,” Cunningham said. He noted that access has been one of the biggest barriers between the development of blood-based testing technologies and the patients who need them.

According to Cunningham, the partnership is intended to help address this challenge by expanding the availability of LucentAD Complete through an established laboratory network. Greater access to testing could help patients and their physicians obtain earlier answers and make more informed decisions about subsequent care.

The agreement also reflects Quanterix’s broader efforts to increase the clinical availability of its biomarker technologies. While scientific advances have helped improve the ability to identify biological indicators associated with neurological diseases, ensuring that these tools are accessible through healthcare providers remains an important part of translating innovation into clinical practice.

By working with Sherman Abrams Laboratory, Quanterix aims to strengthen the distribution and availability of its Alzheimer’s blood testing services in a major metropolitan healthcare market.

Significant Alzheimer’s Disease Burden Across the New York Region

The partnership comes as Alzheimer’s disease continues to represent a major public health challenge across the United States. According to the Alzheimer’s Association, more than 676,800 people aged 65 and older are already living with Alzheimer’s disease across New York, New Jersey, and Connecticut.

This substantial regional disease burden highlights the need for accessible diagnostic resources that can support physicians in identifying and evaluating individuals with potential signs of Alzheimer’s disease.

Many people experiencing early cognitive changes may not immediately receive a formal diagnosis. Symptoms such as memory difficulties, confusion, and changes in thinking can develop gradually and may initially be attributed to normal aging or other health conditions. As a result, some individuals may experience delays in obtaining a comprehensive clinical evaluation.

Increasing access to blood-based biomarker testing could help address certain barriers by providing physicians with another diagnostic tool when assessing patients with suspected Alzheimer’s disease. These tests may contribute additional biological information that can be considered alongside clinical history, cognitive assessments, and other relevant findings.

The distribution agreement specifically focuses on individuals who exhibit signs of Alzheimer’s disease or may be at risk but have not yet been formally diagnosed. By making LucentAD Complete available through its referring physician network, Sherman Abrams Laboratory aims to help healthcare professionals incorporate advanced biomarker testing into appropriate patient evaluations.

However, blood-based biomarker testing is not intended to replace a complete medical assessment. Physicians must interpret test results in the context of each patient’s symptoms, medical history, and other diagnostic information.

Sherman Abrams Laboratory to Leverage Its Physician Network

Sherman Abrams Laboratory will play a central role in expanding the availability of LucentAD Complete throughout the Metro New York and New Jersey region.

Based in Brooklyn, New York, the laboratory provides clinical and anatomic pathology services and maintains relationships with a broad network of referring physicians. Through the exclusive arrangement, the laboratory will offer Quanterix’s Alzheimer’s blood testing to physicians across its established service area.

The collaboration is intended to connect advanced biomarker testing technology with healthcare professionals who regularly evaluate patients for neurological and other medical conditions. By incorporating LucentAD Complete into its testing portfolio, Sherman Abrams Laboratory will provide physicians with access to an additional tool for assessing Alzheimer’s-related biomarkers.

Sal Prifitera, Executive Vice President and Chief Business Officer of Sherman Abrams Laboratory, expressed enthusiasm about the collaboration and its potential to improve diagnostic capabilities for physicians and patients.

“We are excited to partner with Quanterix to bring this innovative Alzheimer’s blood testing technology to the physicians and patients we serve,” Prifitera said.

He added that the partnership reflects the laboratory’s continued commitment to advancing diagnostic capabilities, improving access to innovative testing technologies, and helping physicians make more informed decisions for their patients.

For Sherman Abrams Laboratory, the agreement represents an opportunity to broaden its diagnostic service offerings while supporting the growing demand for accessible testing solutions related to neurological diseases. The laboratory’s physician network is expected to provide an important channel for making LucentAD Complete available to patients across the region.

Blood Biomarkers and the Evolving Alzheimer’s Diagnostic Landscape

The development of blood-based biomarkers is an increasingly important area of Alzheimer’s disease research and diagnostics. Scientists and diagnostic companies are working to identify measurable biological indicators that may help characterize changes associated with the disease.

Biomarkers such as phosphorylated tau and amyloid-beta are among the biological measures being studied in connection with Alzheimer’s pathology. These proteins and their related forms can provide information about processes associated with the disease.

Quanterix’s SIMOA technology is designed to detect biomarkers at very low concentrations, making it suitable for applications where sensitive measurement is important. LucentAD Complete uses this platform to assess multiple biomarkers associated with Alzheimer’s disease through blood-based testing.

The ability to evaluate several biomarkers may provide physicians with additional information compared with approaches that rely on a single biological indicator. Such information can support a more comprehensive assessment of disease-related risk when interpreted alongside other clinical findings.

As the field continues to advance, blood-based testing is expected to play an increasingly important role in discussions about earlier identification, patient evaluation, and access to Alzheimer’s-related diagnostics. Partnerships between diagnostic technology developers and established clinical laboratories may help bring these innovations into broader healthcare settings.

The Quanterix and Sherman Abrams Laboratory agreement is aligned with this development by focusing on practical distribution and access. Rather than limiting the availability of the test to a narrow group of specialized facilities, the arrangement will use an existing physician referral network to reach a wider patient population.

Partnership Supports Broader Availability of LucentAD Complete

The exclusive distribution agreement establishes a commercial collaboration between Quanterix and Sherman Abrams Laboratory with the shared objective of improving access to advanced Alzheimer’s disease testing.

For Quanterix, the partnership provides an opportunity to extend the reach of LucentAD Complete through a regional laboratory partner with an established network of healthcare professionals. For Sherman Abrams Laboratory, the agreement adds an innovative blood-based Alzheimer’s diagnostic offering to its services and supports its efforts to expand access to advanced testing.

The companies expect the arrangement to help physicians obtain additional information when evaluating patients with potential Alzheimer’s-related symptoms or risk factors. Greater availability of testing may also help patients and families engage in more informed discussions with healthcare professionals about diagnostic evaluation and appropriate next steps.

As Alzheimer’s disease continues to affect hundreds of thousands of older adults across the New York, New Jersey, and Connecticut region, improving access to diagnostic resources remains an important healthcare priority. The partnership is intended to contribute to that effort by making LucentAD Complete available to more physicians and patients throughout the region.

About Quanterix
Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits.

With approximately 6,300 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,439 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue – advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com.

About Sherman Abrams
Established in 1964, Sherman Abrams Labs is Brooklyn’s foremost full service clinical and anatomic pathology laboratory. Community based, it provides laboratory service to its patients, physician offices, nursing homes, adult homes, hospitals, rehabilitation centers, dialysis centers and home-bound patients. Sherman Abrams continues to grow through its focus on offering personalized health care, and heavy investment in state-of-the-art technology and its employees.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter